With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech's board and management have determined that CGM technology and ...

The additional liquidity will support both the continued development of Trinity Biotech’s innovative continuous glucose monitoring (CGM) technology and the Company Trinity Biotech’s patented ...

Trinity Biotech (TRIB) received notice from the Nasdaq Stock Market LLC that the company is not in compliance with Nasdaq ...

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market.

In other recent news, Trinity Biotech has secured an additional $4 million in debt financing from Perceptive Advisors to advance its continuous glucose monitoring (CGM) technology and ...

The firm has a market cap of $10.47 million, a P/E ratio of -0.26 and a beta of 1.21. Trinity Biotech has a 12 month low of $0.48 and a 12 month high of $3.55. The stock has a 50-day moving ...

With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech's board and management have determined that CGM technology and ...

The company aims to use this process to improve the functionality of its glucose biosensor in its next-gen CGM technology. Tuesday, Trinity Biotech plc (NASDAQ:TRIB) stock is trading higher with a ...

In other recent news, Trinity Biotech has secured an additional $4 million in debt financing from Perceptive Advisors to advance its continuous glucose monitoring (CGM) technology and transformation ...

The additional liquidity will support both the continued development of Trinity Biotech’s innovative continuous glucose monitoring (CGM) technology and the Company Trinity Biotech’s patented ...